… We evaluated 352 patients who had acute major bleeding within 18 hours after administration
of a factor Xa inhibitor. The patients received a bolus of andexanet, followed by a 2-hour …

… -4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) …
cohort study that evaluated andexanet alfa in patients with acute major bleeding. The results of …

… of andexanet alfa or prothrombin complex concentrate to reverse factor Xa inhibitor-associated
acute major bleeding, … Neither reversal agent was significantly associated with increased …

… has been available for oral factor Xa (FXa) inhibitors until recently. Andexanet alfa was approved
in May … The ability of andexanet alfa to reverse other Factor Xa inhibitors and to improve …

… andexanet alfa. This article will review the data supporting andexanet alfa, encompassing all
andexanet alfa … clinical use, and discuss implications for the clinical use of andexanet alfa. …

… Andexanet alfa (andexanet) and prothrombin complex concentrate (PCC) are both reversal
agents for major bleeding in patients using factor Xa inhibitors (… safety of andexanet and PCC …

… and outcomes associated with managing oral factor Xa inhibitor (FXai)-related major bleeds.
… 525x) to identify major bleed hospitalizations related to FXai use. Patient demographics, …

… bleeding is based on different factors, as patient presentation is highly variable. Reversal with
andexanet alfa for intracranial hemorrhage at … FXa inhibitor reversal with andexanet alfa in …

… real-world utilization of andexanet alfa is limited. We present our experience with andexanet
alfa use in factor Xa inhibitor associated intracranial hemorrhage. The objective of this study …

… major bleeding event who received andexanet alfa for the reversal of apixaban or rivaroxaban
… 4F-PCC for the reversal of FXa-inhibitor-related bleeding they were included in this study. …